United States
|
|
| Product Center | |
 BC [Burkholderia (Pseudomonas) cepacia] Agar |
|
| Cat. # | Desc. | Qty. | Unit |
| 297755 | BC [Burkholderia (Pseudomonas) cepacia] Agar | 20 | SP |
PC Agar and OFPBL Agar are used in the selective isolation and detection of Burkholderia (formerly Pseudomonas) cepacia from clinical and nonclinical specimens.
| Catalog # | Description | Quantity | Unit |
| 297755 | BC [Burkholderia (Pseudomonas) cepacia] Agar | 20 | SP |
PC Agar and OFPBL Agar are used in the selective isolation and detection of Burkholderia (formerly Pseudomonas) cepacia from clinical and nonclinical specimens. PC Agar and OFPBL Agar are used in the selective isolation and detection of Burkholderia (formerly Pseudomonas) cepacia from clinical and nonclinical specimens. Burkholderia cepacia is an opportunistic pathogen generally associated with nosocomial infections.1 Studies indicate that B. cepacia may be an important pulmonary pathogen for patients with cystic fibrosis (CF).2 The incidence of this organism in the respiratory tract of CF patients is often accompanied by rapid deterioration in pulmonary status and death.3 Recovery of this organism on commonly-used media, such as blood agar or MacConkey Agar, is difficult because common isolates, such as Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus, overgrow the slower-growing colonies of B. cepacia and mask its presence. Gilligan et al. developed PC Agar for improved recovery of B. cepacia.2 Crystal violet, bile salts and two antimicrobial agents are used as selective agents. Phenol red facilitates detection of B. cepacia by a color change in the medium. They reported isolating B. cepacia on PC Agar from respiratory secretions of 35 CF patients, but isolated the organism from only 21 patients on MacConkey Agar.2 Welch et al. developed a differential but less selective medium for the recovery of B. cepacia.4,5 This medium, OFPBL Agar, is OF (oxidation-fermentation) basal medium supplemented with polymyxin B, bacitracin, lactose and agar. The indicator, bromthymol blue, aids in the detection of B. cepacia isolates through a color change in the medium. These investigators reported isolating B. cepacia on OFPBL Agar from 58 CF patients, while only isolating this organism from 19 patients on MacConkey Agar.4 Burkholderia cepacia is an opportunistic pathogen generally associated with nosocomial infections.1 Studies indicate that B. cepacia may be an important pulmonary pathogen for patients with cystic fibrosis (CF).2 The incidence of this organism in the respiratory tract of CF patients is often accompanied by rapid deterioration in pulmonary status and death.3 Recovery of this organism on commonly-used media, such as blood agar or MacConkey Agar, is difficult because common isolates, such as Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus, overgrow the slower-growing colonies of B. cepacia and mask its presence. Gilligan et al. developed PC Agar for improved recovery of B. cepacia.2 Crystal violet, bile salts and two antimicrobial agents are used as selective agents. Phenol red facilitates detection of B. cepacia by a color change in the medium. They reported isolating B. cepacia on PC Agar from respiratory secretions of 35 CF patients, but isolated the organism from only 21 patients on MacConkey Agar.2 Welch et al. developed a differential but less selective medium for the recovery of B. cepacia.4,5 This medium, OFPBL Agar, is OF (oxidation-fermentation) basal medium supplemented with polymyxin B, bacitracin, lactose and agar. The indicator, bromthymol blue, aids in the detection of B. cepacia isolates through a color change in the medium. These investigators reported isolating B. cepacia on OFPBL Agar from 58 CF patients, while only isolating this organism from 19 patients on MacConkey Agar.4 1. Examine plates for signs of deterioration as described under "Product Deterioration." 2. Check performance by inoculating a representative sample of plates with pure cultures of stable control organisms that produce known, desired reactions. The following test strains are recommended:
Quality control requirements must be performed in accordance with applicable local, state and/or federal regulations or accreditation requirements and your laboratory's standard Quality Control procedures. It is recommended that the user refer to pertinent NCCLS guidance and CLIA regulations for appropriate Quality Control practices.
For in vitro Diagnostic Use. If excessive moisture is observed, invert the bottom over an off-set lid and allow to air dry in order to prevent formation of a seal between the top and bottom of the plate during incubation. Pathogenic microorganisms, including hepatitis viruses and Human Immunodeficiency Virus, may be present in clinical specimens. "Standard Precautions"6-9 and institutional guidelines should be followed in handling all items contaminated with blood and other body fluids. Prior to discarding, sterilize prepared plates, specimen containers and other contaminated materials by autoclaving. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Information shown on this page is a short summary extracted from the Package Insert, available as a PDF under the Related Documents section of this page.
